These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38760637)

  • 1. Making Information About Cladribine Tablets Accessible to People with Multiple Sclerosis: A Patient-Survey-Led Narrative Review for Healthcare Professionals.
    Shephard A; Kolaczkowski L; Barker N; Nahal D; Oreja-Guevara C; Reyes S; Gray H; Salloukh H; Giovannoni G
    Neurol Ther; 2024 Aug; 13(4):1015-1038. PubMed ID: 38760637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Targeted Literature Search and Phenomenological Review of Perspectives of People with Multiple Sclerosis and Healthcare Professionals of the Immunology of Disease-Modifying Therapies.
    Burtchell J; Clemmons D; Clemmons J; Sabutis T; Rosenberg A; Graves J; Sweeney ML; Kramer J; Ziehn M; Brown B; Weiss JL; Obeidat AZ
    Neurol Ther; 2022 Sep; 11(3):955-979. PubMed ID: 35608740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets.
    Schmierer K; Wiendl H; Oreja-Guevara C; Centonze D; Chudecka A; Roy S; Boschert U
    Neurodegener Dis Manag; 2023 Feb; 13(1):15-21. PubMed ID: 36545912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cladribine tablets in people with relapsing multiple sclerosis: A real-world multicentric study from southeast European MS centers.
    Adamec I; Brecl Jakob G; Rajda C; Drulović J; Radulović L; Bašić Kes V; Lazibat I; Rimac J; Cindrić I; Gržinčić T; Abičić A; Barun B; Gabelić T; Gomezelj S; Mesaroš Š; Pekmezović T; Klivényi P; Krbot Skorić M; Habek M
    J Neuroimmunol; 2023 Sep; 382():578164. PubMed ID: 37536052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Side effects that occurred early in people with multiple sclerosis during the first year of treatment with cladribine tablets: a plain language summary.
    Oh J; Walker B; Giovannoni G; Jack D; Dangond F; Nolting A; Aldridge J; Lebson LA; Leist TP
    Neurodegener Dis Manag; 2022 Feb; 12(1):1-7. PubMed ID: 35019731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with Cladribine Tablets Beyond Year 4: A Position Statement by Southeast European Multiple Sclerosis Centers.
    Habek M; Drulovic J; Brecl Jakob G; Barbov I; Radulovic L; Rajda C; Rejdak K; Turčáni P
    Neurol Ther; 2023 Feb; 12(1):25-37. PubMed ID: 36394714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CLICK-MS and MASTER-2 Phase IV trial design: cladribine tablets in suboptimally controlled relapsing multiple sclerosis.
    Miravalle AA; Katz J; Robertson D; Hayward B; Harlow DE; Lebson LA; Sloane JA; Bass AD; Fox EJ
    Neurodegener Dis Manag; 2021 Apr; 11(2):99-111. PubMed ID: 33517769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry.
    Spelman T; Ozakbas S; Alroughani R; Terzi M; Hodgkinson S; Laureys G; Kalincik T; Van Der Walt A; Yamout B; Lechner-Scott J; Soysal A; Kuhle J; Sanchez-Menoyo JL; Blanco Morgado Y; Spitaleri D; van Pesch V; Horakova D; Ampapa R; Patti F; Macdonell R; Al-Asmi A; Gerlach O; Oh J; Altintas A; Tundia N; Wong SL; Butzkueven H
    Mult Scler; 2023 Feb; 29(2):221-235. PubMed ID: 36433775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of cladribine tablets in people with more active multiple sclerosis: a plain language summary.
    Vermersch P; Galazka A; Dangond F; Damian D; Wong SL; Jack D; Harty G
    Neurodegener Dis Manag; 2022 Dec; 12(6):285-293. PubMed ID: 35920065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5 years: a plain language summary.
    Stefano N; Sormani MP; Giovannoni G; Rammohan K; Leist TP; Coyle PK; Dangond F; Alexandri N; Galazka A
    Neurodegener Dis Manag; 2022 Dec; 12(6):303-310. PubMed ID: 36017797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis.
    Brochet B; Hupperts R; Langdon D; Solari A; Piehl F; Lechner-Scott J; Montalban X; Selmaj K; Valis M; Rejdak K; Havrdova EK; Patti F; Alexandri N; Nolting A; Keller B
    Mult Scler Relat Disord; 2022 Jan; 57():103385. PubMed ID: 35158476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary.
    Rieckmann P; Centonze D; Giovannoni G; Hua LH; Oreja-Guevara C; Selchen D; Sørensen PS; Vermersch P; Wiendl H; Salloukh H; Yamout B
    Neurodegener Dis Manag; 2023 Feb; 13(1):5-13. PubMed ID: 36278394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caregiver Involvement in MS: Duty or Disruption?
    Kesselring J; Boyko A; Laroni A; Bharadia T; van Galen P; Alexandri N
    Neurol Ther; 2022 Mar; 11(1):9-20. PubMed ID: 34792783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study.
    Giovannoni G; Boyko A; Correale J; Edan G; Freedman MS; Montalban X; Rammohan K; Stefoski D; Yamout B; Leist T; Aydemir A; Borsi L; di Cantogno EV
    Neurodegener Dis Manag; 2023 Oct; 13(5):261-268. PubMed ID: 37535336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study.
    Sorensen PS; Pontieri L; Joensen H; Heick A; Rasmussen PV; Schäfer J; Ratzer R; Pihl CE; Sellebjerg F; Magyari M
    Mult Scler Relat Disord; 2023 Feb; 70():104491. PubMed ID: 36623393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expert opinion on the use of cladribine tablets in clinical practice.
    Sørensen PS; Centonze D; Giovannoni G; Montalban X; Selchen D; Vermersch P; Wiendl H; Yamout B; Salloukh H; Rieckmann P
    Ther Adv Neurol Disord; 2020; 13():1756286420935019. PubMed ID: 32636933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: A combined perspective from the MS in the 21st Century Steering Group.
    ; Rieckmann P; Centonze D; Elovaara I; Giovannoni G; Havrdová E; Kesselring J; Kobelt G; Langdon D; Morrow SA; Oreja-Guevara C; Schippling S; Thalheim C; Thompson H; Vermersch P; Aston K; Bauer B; Demory C; Giambastiani MP; Hlavacova J; Nouvet-Gire J; Pepper G; Pontaga M; Rogan E; Rogalski C; van Galen P; Ben-Amor AF
    Mult Scler Relat Disord; 2018 Jan; 19():153-160. PubMed ID: 29241142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expert-Agreed Practical Recommendations on the Use of Cladribine.
    Meca-Lallana V; García Domínguez JM; López Ruiz R; Martín-Martínez J; Arés Luque A; Hernández Pérez MA; Prieto González JM; Landete Pascual L; Sastre-Garriga J
    Neurol Ther; 2022 Dec; 11(4):1475-1488. PubMed ID: 36068429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Position of Cladribine Tablets in the Management of Relapsing-Remitting Multiple Sclerosis: An Expert Narrative Review From the United Arab Emirates.
    Inshasi JS; Alfahad S; Alsaadi T; Hassan A; Zein T; Mifsud VA; Nouri SI; Shakra M; Shatila AO; Szolics M; Thakre M; Kumar A; Boshra A
    Neurol Ther; 2021 Dec; 10(2):435-454. PubMed ID: 33891277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease stability over five years in people with multiple sclerosis treated with cladribine tablets: a plain language summary.
    Giovannoni G; Comi G; Rammohan K; Rieckmann P; Dangond F; Jack D; Vermersch P
    Neurodegener Dis Manag; 2022 Dec; 12(6):295-301. PubMed ID: 36017780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.